Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.

Michele WilsonCheryl McDadeAnna Trisia Beby-HeijtelAngela Waterval-OverbeekVishalini SundaramJohnna E Perdrizet

Published in: Infectious diseases and therapy (2023)

For the Dutch pediatric NIP, switching to PCV13 in 2023 would be an effective strategy compared with continued use of PCV10 for averting pneumococcal disease cases. Switching to PCV20 in 2024 was estimated to avert the most pneumococcal disease cases and provide the highest protection. However, in the face of budget constraints and the undervaluation of prevention strategies, it remains challenging to implement higher valent vaccines. Further research is needed to understand the cost-effectiveness and feasibility of a sequential approach.

Keyphrases

public health
young adults
cancer therapy
drug delivery
childhood cancer